ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries. Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients. Materials and met...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongbo Zhang, Tingting Chen, Lizhu Shan
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2019
Materias:	shenqi fuzheng injection adjunctive treatment chemotherapy breast cancer meta-analysis Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6d1d4cdbd1e44088a3ce2d1ccd1417ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6d1d4cdbd1e44088a3ce2d1ccd1417ed
record_format	dspace
spelling	oai:doaj.org-article:6d1d4cdbd1e44088a3ce2d1ccd1417ed2021-11-17T14:21:56ZShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis1388-02091744-511610.1080/13880209.2019.1660383https://doaj.org/article/6d1d4cdbd1e44088a3ce2d1ccd1417ed2019-01-01T00:00:00Zhttp://dx.doi.org/10.1080/13880209.2019.1660383https://doaj.org/toc/1388-0209https://doaj.org/toc/1744-5116Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries. Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients. Materials and methods: Both English and Chinese databases were searched covering the time period of 1999– 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale. Results: Forty-nine trials were included based on certain selection criteria. Only seven studies were rated as high-quality publications. Results of meta-analysis showed that SFI intervention can significantly improve objective tumour response, performance status, NK, CD3+, CD4+ and CD4+/CD8+ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes. However, no significant difference was found between SFI and the control group regarding CD8+ levels, and renal disorders. Discussion and conclusions: SFI intervention appeared to be effective in improving clinical efficacy, immune function and reducing toxicity when combined with chemotherapy for breast cancer. However, our findings still need verification by high-quality trials.Hongbo ZhangTingting ChenLizhu ShanTaylor & Francis Grouparticleshenqi fuzheng injectionadjunctive treatmentchemotherapybreast cancermeta-analysisTherapeutics. PharmacologyRM1-950ENPharmaceutical Biology, Vol 57, Iss 1, Pp 612-624 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	shenqi fuzheng injection adjunctive treatment chemotherapy breast cancer meta-analysis Therapeutics. Pharmacology RM1-950
spellingShingle	shenqi fuzheng injection adjunctive treatment chemotherapy breast cancer meta-analysis Therapeutics. Pharmacology RM1-950 Hongbo Zhang Tingting Chen Lizhu Shan ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
description	Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries. Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients. Materials and methods: Both English and Chinese databases were searched covering the time period of 1999– 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale. Results: Forty-nine trials were included based on certain selection criteria. Only seven studies were rated as high-quality publications. Results of meta-analysis showed that SFI intervention can significantly improve objective tumour response, performance status, NK, CD3+, CD4+ and CD4+/CD8+ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes. However, no significant difference was found between SFI and the control group regarding CD8+ levels, and renal disorders. Discussion and conclusions: SFI intervention appeared to be effective in improving clinical efficacy, immune function and reducing toxicity when combined with chemotherapy for breast cancer. However, our findings still need verification by high-quality trials.
format	article
author	Hongbo Zhang Tingting Chen Lizhu Shan
author_facet	Hongbo Zhang Tingting Chen Lizhu Shan
author_sort	Hongbo Zhang
title	ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
title_short	ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
title_full	ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
title_fullStr	ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
title_full_unstemmed	ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
title_sort	shenqi fuzheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
publisher	Taylor & Francis Group
publishDate	2019
url	https://doaj.org/article/6d1d4cdbd1e44088a3ce2d1ccd1417ed
work_keys_str_mv	AT hongbozhang shenqifuzhenginjectionasanadjunctivetreatmenttochemotherapyinbreastcancerpatientsametaanalysis AT tingtingchen shenqifuzhenginjectionasanadjunctivetreatmenttochemotherapyinbreastcancerpatientsametaanalysis AT lizhushan shenqifuzhenginjectionasanadjunctivetreatmenttochemotherapyinbreastcancerpatientsametaanalysis
_version_	1718425489418223616

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis

Ejemplares similares